We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for ruxolitinib (as phosphate) (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
ruxolitinib (as phosphate)
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
tablets
Indication
Jakavi is indicated for the treatment of patients with Graft versus Host Disease (GvHD).
Therapeutic area
Immunology